Richard Kanner

Prof. Richard Kanner

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2014 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
WOWanda K O’nEal
Wanda K O’nEal
WAWayne Anderson
Wayne Anderson
PBPatricia V Basta
Patricia V Basta
ECElizabeth E Carretta
Elizabeth E Carretta
CDClaire M Doerschuk
Claire M Doerschuk
RIreporting for SPIROMICS Investigators
reporting for SPIROMICS Investigators
As a part of the longitudinal Chronic Obstructive Pulmonary Disease (COPD) study, Subpopulations and Intermediate Outcome Measures in COPD study (SPIROMICS), blood samples are being collected from 3200 subjects with the goal of identifying blood biomarkers for sub-phenotyping patients and predicting disease progression. To determine the most reliable sample type for measuring specific blood analytes in the cohort, a pilot study was performed from a subset of 24 subjects comparing serum, Ethylenediaminetetraacetic acid (EDTA) plasma, and EDTA plasma with proteinase inhibitors (P100TM).

1 August 2018 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
FGfor the SPIROMICS Research Group
for the SPIROMICS Research Group
XLXingnan Li
Xingnan Li
VOVictor E. Ortega
Victor E. Ortega
EAElizabeth J. Ampleford
Elizabeth J. Ampleford
RBR. Graham Barr
R. Graham Barr
DMDeborah A. Meyers
Deborah A. Meyers
The aim of this study is to identify genetic loci associated with post-bronchodilator FEV1/FVC and FEV1, and develop a multi-gene predictive model for lung function in COPD. Genome-wide association study (GWAS) of post-bronchodilator FEV1/FVC and FEV1 was performed in 1645 non-Hispanic White European descent smokers. A functional rare variant in SERPINA1 (rs28929474: Glu342Lys) was significantly associated with post-bronchodilator FEV1/FVC (p = 1.2 × 10− 8) and FEV1 (p = 2.1 × 10− 9). In addition, this variant was associated with COPD (OR = 2.3; p = 7.8 × 10− 4) and severity (OR = 4.1; p = 0.0036). Heterozygous subjects (CT genotype) had significantly lower lung function and higher percentage of COPD and more severe COPD than subjects with the CC genotype. 8.6% of the variance of post-bronchodilator FEV1/FVC can be explained by SNPs in 10 genes with age, sex, and pack-years of cigarette smoking (P < 2.2 × 10− 16). This study is the first to show genome-wide significant association of rs28929474 in SERPINA1 with lung function. Of clinical importance, heterozygotes of rs28929474 (4.7% of subjects) have significantly reduced pulmonary function, demonstrating a major impact in smokers. The multi-gene model is significantly associated with CT-based emphysema and clinical outcome measures of severity. Combining genetic information with demographic and environmental factors will further increase the predictive power for assessing reduced lung function and COPD severity.

CPCheryl Pirozzi
Cheryl Pirozzi
ASAnne Sturrock
Anne Sturrock
HWHsin-Yi Weng
Hsin-Yi Weng
TGTom Greene
Tom Greene
MSMary Beth Scholand
Mary Beth Scholand
RIRobert Paine Iii
Robert Paine Iii
This study aimed to determine if naturally occurring episodes of ozone air pollution in the Salt Lake Valley in Utah, USA, during the summer are associated with increased pulmonary inflammation and oxidative stress, increased respiratory symptoms, and decreased lung function in individuals with chronic obstructive pulmonary disease (COPD) compared to controls. We measured biomarkers (nitrite/nitrate (NOx), 8-isoprostane) in exhaled breath condensate (EBC), spirometry, and respiratory symptoms in 11 former smokers with moderate-to-severe COPD and nine former smokers without airflow obstruction during periods of low and high ozone air pollution. High ozone levels were associated with increased NOx in EBC in both COPD (8.7 (±8.5) vs. 28.6 (±17.6) μmol/L on clean air vs. pollution days, respectively, p < 0.01) and control participants (7.6 (±16.5) vs. 28.5 (±15.6) μmol/L on clean air vs. pollution days, respectively, p = 0.02). There was no difference in pollution effect between COPD and control groups, and no difference in EBC 8-isoprostane, pulmonary function, or respiratory symptoms between clean air and pollution days in either group. Former smokers both with and without airflow obstruction developed airway oxidative stress and inflammation in association with ozone air pollution episodes.

19 March 2022 in Science of The Total Environment
Verified
Journal Article
Closed access
DBDaniel C. Belz
Daniel C. Belz
HWHan Woo
Han Woo
NPNirupama Putcha
Nirupama Putcha
LPLaura M. Paulin
Laura M. Paulin
KKKirsten Koehler
Kirsten Koehler
NHNadia Hansel
Nadia Hansel

20 November 2018 in Respiratory Research
Verified
Journal Article
Open access
PDF file
CPCheryl Pirozzi
Cheryl Pirozzi
TGTian Gu
Tian Gu
PQPedro M. Quibrera
Pedro M. Quibrera
ECElizabeth E. Carretta
Elizabeth E. Carretta
MHMeiLan K. Han
MeiLan K. Han
RPRobert Paine
Robert Paine
The identification of smoking-related lung disease in current and former smokers with normal FEV1 is complex, leading to debate regarding using a ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC) of less than 0.70 versus the predicted lower limit of normal (LLN) for diagnosis of airflow obstruction. We hypothesized that the discordant group of ever-smokers with FEV1/FVC between the LLN and 0.70 is heterogeneous, and aimed to characterize the burden of smoking-related lung disease in this group. We compared spirometry, chest CT characteristics, and symptoms between 161 ever-smokers in the discordant group and 940 ever-smokers and 190 never-smokers with normal FEV1 and FEV1/FVC > 0.70 in the SPIROMICS cohort. We also estimated sensitivity and specificity for diagnosing objective radiographic evidence of chronic obstructive pulmonary disease (COPD) using different FEV1/FVC criteria thresholds. The discordant group had more CT defined emphysema and non-emphysematous gas trapping, lower post-bronchodilator FEV1 and FEF25–75, and higher respiratory medication use compared with the other two groups. Within the discordant group, 44% had radiographic CT evidence of either emphysema or non-emphysematous gas trapping; an FEV1/FVC threshold of 0.70 has greater sensitivity but lower specificity compared with LLN for identifying individuals with CT abnormality. Ever-smokers with normal FEV1 and FEV1/FVC < 0.70 but > LLN are a heterogeneous group that includes significant numbers of individuals with and without radiographic evidence of smoking-related lung disease. These findings emphasize the limitations of diagnosing COPD based on spirometric criteria alone.

13 March 2009 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
RKRichard Kanner
Richard Kanner